Business Context and Reporting Period
This Form 8-K was filed by OvaScience, Inc. on March 19, 2013, reporting events that occurred on March 18, 2013. The company is incorporated in Delaware and operates from Cambridge, MA. Note: The input metadata references "Tempest Therapeutics, Inc.," but the filing text explicitly identifies the registrant as OvaScience, Inc.
Key Financial Metrics
- Capital Raised: Approximately $35 million in gross proceeds.
- Shares Issued: 3,888,880 shares of common stock.
- Investor Type: Selected institutional and accredited investors.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the consummation of a private placement of common stock. This transaction significantly increased the company's cash position by approximately $35 million and expanded its outstanding share count by 3,888,880 shares.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the disclosure of the capital raise itself. No unusual items were reported in this specific document.
Investor Verification Checklist
- Verify the exact price per share paid by investors to calculate the implied valuation.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the use of proceeds for the $35 million raised in subsequent filings or press releases.
- Check for any registration rights agreements or lock-up periods associated with the institutional investors.